Federica Giammarino

Publications
Public outreach and news

Articles

Article: JOURNAL OF INFECTIOUS DISEASES. 2024;229(6):1796-1802
Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes.
Giammarino F; de Salazar A; Malet I; Viñuela L; Fuentes A; Saladini F; Bartolini N; Charpentier C; Lambert-Niclot S; Sterrantino G; Colao MG; Micheli V; Bertoli A; Fabeni L; Teyssou E; Delgado R; Falces-Romero I; Aguilera A; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin A-G; Moreno C; Zazzi M; García F
Article: MOLECULES. 2024;29(7):1452
Serendipitous Identification of Azine Anticancer Agents Using a Privileged Scaffold Morphing Strategy.
Cesarini S; Vicenti I; Poggialini F; Filippi S; Mancin E; Fiaschi L; De Marchi E; Giammarino F; Vagaggini C; Bizzarri BM; Saladino R; Dreassi E; Zazzi M; Botta L
Article: NEW MICROBIOLOGICA. 2024
PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests"
Panza F; Saladini F; Bartolini N; Giammarino F; Montagnani F; Spagnuolo V; Tumbarello M; Santoro MM; Castagna A; Zazzi M; Fabbiani M
Article: ORGANIC & BIOMOLECULAR CHEMISTRY. 2024;22(4):767-783
Switching the three-component Biginelli-like reaction conditions for the regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines.
Pacetti M; Pismataro MC; Felicetti T; Giammarino F; Bonomini A; Tiecco M; Bertagnin C; Barreca ML; Germani R; Cecchetti V; Vicenti I; Tabarrini O; Zazzi M; Loregian A; Massari S
Article: VIRUSES-BASEL. 2024;16(2):168
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants.
Fiaschi L; Biba C; Varasi I; Bartolini N; Paletti C; Giammarino F; Saladini F; Zazzi M; Vicenti I
Journal article: FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY. 2024;14:1334126
Broad synergistic antiviral efficacy between a novel elite controller-derived dipeptide and antiretrovirals against drug-resistant HIV-1
Giammarino F; Sonnerborg A; Cena-Diez R
Article: CHEMMEDCHEM. 2023;18(16):e202300200
Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties.
Grazia Martina M; Giammarino F; Vicenti I; Groaz E; Rozenski J; Incerti M; Sannio F; Docquier JD; Zazzi M; Radi M
Article: PHARMACEUTICALS. 2023;16(8):1118
HIV-1 Integrase Inhibition Activity by Spiroketals Derived from Plagius flosculosus, an Endemic Plant of Sardinia (Italy) and Corsica (France).
Sanna C; D'Abrosca B; Fiorentino A; Giammarino F; Vicenti I; Corona A; Caredda A; Tramontano E; Esposito F
Article: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 2023;61(3):106737
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
Saladini F; Giammarino F; Maggiolo F; Ferrara M; Cenderello G; Celesia BM; Martellotta F; Spagnuolo V; Corbelli GM; Gianotti N; Santoro MM; Rusconi S; Zazzi M; Castagna A; PRESTIGIO Study Group
Article: MOLECULES. 2022;27(24):8829
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity.
Cesarini S; Vicenti I; Poggialini F; Secchi M; Giammarino F; Varasi I; Lodola C; Zazzi M; Dreassi E; Maga G; Botta L; Saladino R
Article: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2022;91(4):381-389
Dynamics of Total and Intact HIV-1 DNA in Virologically Suppressed Patients Switching to DTG-Based or ATV-Based Dual Therapy.
Dragoni F; Rossetti B; Lombardi F; Spertilli Raffaelli C; Bartolini N; Giammarino F; Moschese D; Di Giambenedetto S; Fabbiani M; De Luca A; Vicenti I; Zazzi M; Saladini F
Article: VACCINES. 2022;10(8):1237
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses.
Parisi SG; Mengoli C; Basso M; Vicenti I; Gatti F; Scaggiante R; Fiaschi L; Giammarino F; Iannetta M; Malagnino V; Zago D; Dragoni F; Zazzi M
Article: VIRUSES-BASEL. 2022;14(7):1374
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021;22(5):2670
Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro.
Boccuto A; Dragoni F; Picarazzi F; Lai A; Della Ventura C; Veo C; Giammarino F; Saladini F; Zehender G; Zazzi M; Mori M; Vicenti I
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021;76(1):130-134
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
Article: SLAS DISCOVERY. 2020;25(5):506-514
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication.
Vicenti I; Dragoni F; Giannini A; Giammarino F; Spinicci M; Saladini F; Boccuto A; Zazzi M
Article: ANTIVIRAL RESEARCH. 2020;175:104708
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro.
Dragoni F; Boccuto A; Picarazzi F; Giannini A; Giammarino F; Saladini F; Mori M; Mastrangelo E; Zazzi M; Vicenti I

All other publications

Letter: JOURNAL OF INFECTION. 2022;84(1):94-118
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals.
Boccuto A; Dragoni F; Bergna A; Ventura CD; Giammarino F; Saladini F; Pezzati L; Zehender G; Zazzi M; Vicenti I; Lai A
Letter: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021;76(12):3310-3312
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir.
Saladini F; Giannini A; Giammarino F; Boccuto A; Dragoni F; Vicenti I; Zazzi M
Published conference paper: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2020;75(9):2547-2553
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients.
Saladini F; Giannini A; Giammarino F; Maggiolo F; Vichi F; Corbelli GM; Galli A; Bigoloni A; Poli A; Santoro MM; Zazzi M; Castagna A

Articles

All other publications

News from KI

Events from KI